EMulate Therapeutics Announces Brett Greene, Veteran in the Psychedelic and Cannabinoid Biotechnology Industry, as a Company Advisor

BELLEVUE, Wash.–(BUSINESS WIRE)–EMulate Therapeutics, Inc. (“EMulate” or the “Company”) is excited to announce that Brett J. Greene will be a new advisor to the Company. He will focus his attention on the Company’s work in mental health therapeutics.

Brett is a proven and recognized entrepreneur and business founder in the psychedelic and cannabinoid biotechnology industry. He began his career at Northeastern University’s Center for Drug Discovery where, as research administrator, he co-managed over $80m in federal grants for endocannabinoid and serotonin-related drug discovery efforts under one of the world’s foremost cannabinoid scientists. During his 12.5 years at Northeastern University, Brett co-founded the psychedelic conference and media company Psymposia, the cannabis company Evokanna, and most recently, Adelia Therapeutics, Inc. After Adelia Therapeutics was acquired by Cybin (CYBN), Brett served as Cybin’s Chief Innovation Officer for 3 years. Evokanna was acquired in 2022 by a private company. Brett continues to advise biotech companies through his consulting firm Au Mind, LLC.

“We are excited to have Brett join EMulate as an advisor while we continue to develop our technology’s numerous potential benefits in the mental health space using our signal recordings of psychedelic compounds,” stated Chris Rivera, CEO of EMulate Therapeutics. “As we move forward in growing the company’s markets and fulfilling our mission statement, I cannot think of a better advisor than Brett to help us meet the challenges of the exciting space of psychedelic therapy using our ulRFE technology.”

“I am really looking forward to working with the EMulate team and with their ulRFE technology to help advance it for patients in need of mental health treatment,” Brett stated. “I believe that the EMulate technology has the potential to have a significant impact for patients and in the psychedelic and mental health markets.”

About EMulate Therapeutics, Inc.

EMulate Therapeutics is a clinical stage company, reshaping the therapeutic treatment landscape with digital medicines. Using its proprietary radio frequency energy technology (RFE) targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®) to emulate the effects of drugs and other therapies in treating patients, without the administration of physical drug substances themselves. The use of ulRFE® has been shown to be safe to date and the potential therapeutic benefits, specifically targeted at patients’ underlying conditions, continue to be evaluated in multiple studies. This versatile, non-invasive platform technology may provide a solution for patients with cancer, acute and chronic pain, mental health disorders and other serious conditions. EMulate Therapeutics is the licensor of its proprietary technology to Hapbee Technologies, Inc. (HAPB: TSVX). Hapbee is a commercial stage consumer wellness-wearable technology company spun out from EMulate in 2019. EMulate is the largest independent shareholder in Hapbee and recipient of quarterly royalties from net sales.

About our ulRFE Device

EMulate Therapeutics (EMTx) has developed a non-sterile, non-invasive, non-thermal, non-ionizing, battery-powered, portable investigational medical device that uses low to ultra-low level (DC-22kHz) frequencies to deliver specific electromagnetic fields to produce specific biological effects, including, e.g., increasing tubulin polymerization in numerous cancer models, emulating the effects of psychedelic drugs in mental health models and reducing pain sensations, among others. The system emits a low power magnetic field (< 100 mG) that can be applied locally or globally, depending on the type of therapeutic effect sought. The EMTX signals are stored as WAV files on the device and emitted via a cable to the attached antenna unit.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements.” Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “could,” “should,” “would,” “plan,” “project,” “forecast,” and “potential,” the negatives thereof or similar expressions. Forward-looking statements speak only as of the date made, are based on various underlying assumptions and current expectations about the future and are not guarantees of future performance. While we believe these assumptions and expectations are reasonable, are made in good faith and have a reasonable basis, assumed facts or bases almost always vary from actual results, and the differences between assumed facts or expectations and actual results can be material, depending on the circumstances. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates, or to regard them as representations that the results or conditions described in such statements will occur or that our objectives and plans will be achieved.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.

Contacts

David Matteson

[email protected]
Cell: 425/478-2121